These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 31126817)
1. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma. Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817 [TBL] [Abstract][Full Text] [Related]
2. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863 [TBL] [Abstract][Full Text] [Related]
3. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer. Liu YL; Gao X; Jiang Y; Zhang G; Sun ZC; Cui BB; Yang YM J Cancer Res Clin Oncol; 2015 Apr; 141(4):661-9. PubMed ID: 25326896 [TBL] [Abstract][Full Text] [Related]
4. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma. Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081 [TBL] [Abstract][Full Text] [Related]
6. Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma. Nakagawa S; Okabe H; Ouchi M; Tokunaga R; Umezaki N; Higashi T; Kaida T; Arima K; Kitano Y; Kuroki H; Mima K; Nitta H; Imai K; Hashimoto D; Yamashita YI; Chikamoto A; Baba H HPB (Oxford); 2018 Oct; 20(10):939-948. PubMed ID: 29759640 [TBL] [Abstract][Full Text] [Related]
7. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications. Kim SH; Yang WI; Min YH; Ko YH; Yoon SO Tumour Biol; 2016 Feb; 37(2):2037-47. PubMed ID: 26337274 [TBL] [Abstract][Full Text] [Related]
8. PRC2-complex related dysfunction in overgrowth syndromes: A review of EZH2, EED, and SUZ12 and their syndromic phenotypes. Cyrus S; Burkardt D; Weaver DD; Gibson WT Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):519-531. PubMed ID: 31724824 [TBL] [Abstract][Full Text] [Related]
9. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns. Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628 [TBL] [Abstract][Full Text] [Related]
10. Non-canonical transcriptional regulation of INHAT subunit SET/TAF-Iβ by EZH2. Hwang IJ; Park J; Seo SB Biochem Biophys Res Commun; 2022 Dec; 635():136-143. PubMed ID: 36274363 [TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412 [TBL] [Abstract][Full Text] [Related]
12. MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis. Ma J; Weng L; Wang Z; Jia Y; Liu B; Wu S; Cao Y; Sun X; Yin X; Shang M; Mao A Exp Cell Res; 2018 May; 366(2):103-113. PubMed ID: 29530475 [TBL] [Abstract][Full Text] [Related]
13. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2. Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470 [TBL] [Abstract][Full Text] [Related]
14. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Li H; Cai Q; Godwin AK; Zhang R Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743 [TBL] [Abstract][Full Text] [Related]
15. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Kirmizis A; Bartley SM; Kuzmichev A; Margueron R; Reinberg D; Green R; Farnham PJ Genes Dev; 2004 Jul; 18(13):1592-605. PubMed ID: 15231737 [TBL] [Abstract][Full Text] [Related]
16. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer. Martin MC; Zeng G; Yu J; Schiltz GE J Med Chem; 2020 Dec; 63(24):15344-15370. PubMed ID: 33283516 [TBL] [Abstract][Full Text] [Related]
17. The JAZF1-SUZ12 fusion protein disrupts PRC2 complexes and impairs chromatin repression during human endometrial stromal tumorogenesis. Ma X; Wang J; Wang J; Ma CX; Gao X; Patriub V; Sklar JL Oncotarget; 2017 Jan; 8(3):4062-4078. PubMed ID: 27845897 [TBL] [Abstract][Full Text] [Related]
18. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. Pasini D; Bracken AP; Jensen MR; Lazzerini Denchi E; Helin K EMBO J; 2004 Oct; 23(20):4061-71. PubMed ID: 15385962 [TBL] [Abstract][Full Text] [Related]
19. Cryptic RNA-binding by PRC2 components EZH2 and SUZ12. Betancur JG; Tomari Y RNA Biol; 2015; 12(9):959-65. PubMed ID: 26177152 [TBL] [Abstract][Full Text] [Related]
20. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer. Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]